Signal Advisors Wealth LLC Buys 210 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Signal Advisors Wealth LLC grew its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 13,764 shares of the company’s stock after acquiring an additional 210 shares during the period. Signal Advisors Wealth LLC’s holdings in GE HealthCare Technologies were worth $1,076,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Quent Capital LLC raised its position in GE HealthCare Technologies by 18.4% in the third quarter. Quent Capital LLC now owns 766 shares of the company’s stock valued at $72,000 after purchasing an additional 119 shares during the last quarter. Greenleaf Trust increased its stake in shares of GE HealthCare Technologies by 1.7% in the third quarter. Greenleaf Trust now owns 7,619 shares of the company’s stock valued at $715,000 after buying an additional 124 shares during the period. Westside Investment Management Inc. raised its holdings in GE HealthCare Technologies by 32.0% in the 3rd quarter. Westside Investment Management Inc. now owns 516 shares of the company’s stock valued at $48,000 after buying an additional 125 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in GE HealthCare Technologies by 8.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company’s stock worth $135,000 after buying an additional 127 shares during the period. Finally, Quarry LP grew its holdings in GE HealthCare Technologies by 28.3% during the 2nd quarter. Quarry LP now owns 594 shares of the company’s stock worth $46,000 after acquiring an additional 131 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

GE HealthCare Technologies stock opened at $84.13 on Wednesday. The stock has a market capitalization of $38.44 billion, a price-to-earnings ratio of 23.11, a PEG ratio of 2.90 and a beta of 1.11. GE HealthCare Technologies Inc. has a 52-week low of $71.31 and a 52-week high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The stock’s 50 day moving average price is $82.13 and its two-hundred day moving average price is $84.27.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business had revenue of $4.86 billion for the quarter, compared to analyst estimates of $4.87 billion. During the same period in the prior year, the firm earned $0.99 earnings per share. GE HealthCare Technologies’s revenue was up .9% on a year-over-year basis. On average, equities analysts predict that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be paid a $0.035 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This is an increase from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a dividend yield of 0.17%. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.85%.

Analysts Set New Price Targets

GEHC has been the subject of several analyst reports. Evercore ISI raised their price target on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Wells Fargo & Company raised their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Wednesday, September 18th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lifted their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average price target of $96.00.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the transaction, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.